FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden hours per response: 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* <u>Maranian Jeffrey R</u> | 2. Date of E Requiring S (Month/Day 07/02/202 | Statement //Year) | 3. Issuer Name and Ticker or Trading Symbol Summit Therapeutics Inc. [SMMT] | | | | | |
|--|--|----------------------|---|----------------------------------|------------------------------------|--|---|--|
| (Last) (First) (Middle) C/O SUMMIT THERAPEUTICS INC. | | | Relationship of Reporting I (Check all applicable) Director | Person(s) to Is | (Mon | 5. If Amendment, Date of Original Filed (Month/Day/Year) | | |
| ONE BROADWAY, 14TH FLOOR | | | X Officer (give title below) | Other (spo | Appli | Applicable Line) | | |
| (Street) CAMBRIDGE MA 02142 (City) (State) (Zip) | | | VP, Corporate C | ontroller | X | Person | y More than One | |
| Table I - Non-Derivative Securities Beneficially Owned | | | | | | | | |
| | | | 2. Amount of Securities Beneficially Owned (Instr. 4) | Form: Dire (D) or Indi | | | ure of Indirect Beneficial rship (Instr. 5) | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | |
| , , , | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | Title and Amount of Securities Underlying Derivative Security (Instr. 4) | | 4. Conversion or Exercise | 5. Ownership Form: Direct (D) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | |
| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | Price of Derivative Security | or Indirect (I) (Instr. 5) | | |
| Stock Option (right to buy) | 11/22/2021 | 11/22/2030 | Common Stock | 112,500(1) | 4.4 | D | | |
| Stock Option (right to buy) | 11/22/2021 | 11/22/2030 | Common Stock | 112,500(2) | 4.4 | D | | |
| Stock Option (right to buy) | 06/01/2022 | 06/16/2031 | Common Stock | 20,000(3) | 6.61 | D | | |

Explanation of Responses:

- 1. The option was granted on November 22, 2020 pursuant to the Issuer's Stock Incentive Plan. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on November 22, 2021.
- 2. The option was granted on November 22, 2020 pursuant to the Issuer's Stock Incentive Plan. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on November 22, 2021, subject to the satisfaction of certain performance targets.
- 3. The option was granted on June 16, 2021 pursuant to the Issuer's Stock Incentive Plan. The shares underlying the option are scheduled to vest in two equal annual installments, with the first such installment occurring on June 1, 2022.

/s/ Jeffrey R. Maranian 07/09/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.